#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis


Autoři: Ninfa Marlen Chaves Torres aff001;  Jecxy Julieth Quijano Rodríguez aff002;  Pablo Sebastián Porras Andrade aff003;  María Belen Arriaga aff004;  Eduardo Martins Netto aff001
Působiště autorů: Department of Medicine and Health, Federal University of Bahia, Salvador, Bahia, Brazil aff001;  Department of Medicine, Nueva Granada Military University, Bogotá, D.C., Colombia aff002;  Department of Biology, The University of Queensland, Brisbane, Australia aff003;  Gonzalo Moniz Institute, Gonzalo Cruz Foundation, Salvador, Bahia, Brazil aff004;  Department of Epidemiology, José Silveira Foundation, Salvador, Bahia, Brazil aff005
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0226507

Souhrn

Objective

To produce pooled estimates of the global results of tuberculosis (TB) treatment and analyze the predictive factors of successful TB treatment.

Methods

Studies published between 2014 and 2019 that reported the results of the treatment of pulmonary TB and the factors that influenced these results. The quality of the studies was evaluated according to the Newcastle-Ottawa quality assessment scale. A random effects model was used to calculate the pooled odds ratio (OR) and 95% confidence interval (CI). This review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) in February 2019 under number CRD42019121512.

Results

A total of 151 studies met the criteria for inclusion in this review. The success rate for the treatment of drug-sensitive TB in adults was 80.1% (95% CI: 78.4–81.7). America had the lowest treatment success rate, 75.9% (95% CI: 73.8–77.9), and Oceania had the highest, 83.9% (95% CI: 75.2–91.0). In children, the success rate was 84.8% (95% CI: 77.7–90.7); in patients coinfected with HIV, it was 71.0% (95% CI: 63.7–77.8), in patients with multidrug-resistant TB, it was 58.4% (95% CI: 51.4–64.6), in patients with and extensively drug-resistant TB it was 27.1% (12.7–44.5). Patients with negative sputum smears two months after treatment were almost three times more likely to be successfully treated (OR 2.7; 1.5–4.8), whereas patients younger than 65 years (OR 2.0; 1.7–2.4), nondrinkers (OR 2.0; 1.6–2.4) and HIV-negative patients (OR 1.9; 1.6–2.5 3) were two times more likely to be successfully treated.

Conclusion

The success of TB treatment at the global level was good, but was still below the defined threshold of 85%. Factors such as age, sex, alcohol consumption, smoking, lack of sputum conversion at two months of treatment and HIV affected the success of TB treatment.

Klíčová slova:

Alcohol consumption – Drug therapy – Extensively drug-resistant tuberculosis – China – Sputum – Tuberculosis


Zdroje

1. World Health Organization. Global tuberculosis report 2018. In. Geneva, Swizerland: WHO; 2018.

2. World Health Organization. WHO End TB Strategy [Internet]. 2015. Available from: www.who.int/tb/post2015_strategy/en/

3. Cox H, Nicol MP. Comment Tuberculosis eradication: renewed commitment and global investment required. Lancet Infect Dis. 2018;18(3):228–9. doi: 10.1016/S1473-3099(17)30692-8 29223584

4. World Health Organization. Global Health Observatory data repository [Internet]. Treatment coverage Data by WHO region. 2019. Available from: https://apps.who.int/gho/data/view.main.57056ALL

5. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses [Internet]. The Ottawa Hospital—Research Institute. 2009. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

6. World Health Organization. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis. 2001;5(3):213–215. 11326818

7. Adane K, Spigt M, Dinant G.J. Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: A five-year retrospective analysis. BMC Pulm Med [Internet]. 2018;18(1). https://doi.org/10.1186/s12890-018-0600-1

8. Ali MK, Karanja S, Karama M. Factors associated with tuberculosis treatment outcomes among tuberculosis patients attending tuberculosis treatment centres in 2016–2017 in Mogadishu, Somalia. Pan Afr Med J. 2017;28:1–14.

9. Amante TD, Ahemed TA. Risk factors for unsuccessful tuberculosis treatment outcome (failure, default and death) in public health institutions, Eastern Ethiopia. Pan Afr Med J. 2015;20:247. doi: 10.11604/pamj.2015.20.247.3345 26161170

10. Budgell EP, Evans D, Schnippel K, Ive P, Long L, Rosen S. Outcomes of treatment of drug-susceptible tuberculosis at public sector primary healthcare clinics in Johannesburg, South Africa: A retrospective cohort study. South African Med J [Internet]. 2016;106(10):1002–9.

11. Ogbudebe CL, Izuogu S, Abu CE. Magnitude and treatment outcomes of pulmonary tuberculosis patients in a poor urban slum of Abia State, Nigeria. Int J Mycobacteriology [Internet]. 2016 Jun;5(2):205–10. https://doi.org/10.1016/j.ijmyco.2016.03.003

12. Ejeta E, Beyene G, Balay G, Bonsa Z, Abebe G. Factors associated with unsuccessful treatment outcome in tuberculosis patients among refugees and their surrounding communities in Gambella Regional State, Ethiopia. PLoS One [Internet]. 2018;13(10). https://doi.org/10.1371/journal.pone.0205468

13. El-Shabrawy M, El-Shafei DA. Evaluation of treatment failure outcome and its predictors among pulmonary tuberculosis patients in Sharkia Governorate, 2013–2014. Egypt J Chest Dis Tuberc [Internet]. 2017;66(1):145–52. https://doi.org/10.1016/j.ejcdt.2015.11.002

14. Ershova J V, Podewils LJ, Bronner LE, Stockwell HG, Dlamini S, Mametja LD. Evaluation of adherence to national treatment guidelines among tuberculosis patients in three provinces of South Africa. SAMJ South African Med J [Internet]. 2014;104(5):362–8. doi: 10.7196/SAMJ.7655 25212205

15. Esmael A, Tsegaye G, Wubie M, Abera H, Endris M. Treatment outcomes of tuberculosis patients in Debre Markos Referral Hospital, north west Ethiopia (June 2008-August 2013): A five year retrospective study. Int J Pharm Sci Res [Internet]. 2014;5(4):1500–5. doi: 10.13040/IJPSR.0975-8232.5(4).1500-05

16. Gebrezgabiher G, Romha G, Ejeta E, Asebe G, Zemene E, Ameni G. Treatment Outcome of Tuberculosis Patients under Directly Observed Treatment Short Course and Factors Affecting Outcome in Southern Ethiopia: A Five-Year Retrospective Study. PLoS One [Internet]. 2016;11(2):e0150560. doi: 10.1371/journal.pone.0150560 26918458

17. Kosgei RJ, Sitienei JK, Kipruto H, Kimenye K, Gathara D, Odawa FX, et al. Gender differences in treatment outcomes among 15–49 year olds with smear-positive pulmonary tuberculosis in Kenya. Int J Tuberc Lung Dis [Internet]. 2015;19(10):1176–81. https://doi.org/10.5588/ijtld.15.0070

18. Mbatchou BH, Dahirou F, Tchieche C, Wandji A, Ngnié C, Nana-Metchedjin A, et al. Clinical characteristics and outcomes of tuberculosis in Douala, Cameroon: A 7-year retrospective cohort study. Int J Tuberc Lung Dis [Internet]. 2016 Dec;20(12):1609–14. https://doi.org/10.5588/ijtld.15.0731

19. Mhimbira F, Hella J, Maroa T, Kisandu S, Chiryamkubi M, Said K, et al. Home-Based and Facility-Based Directly Observed Therapy of Tuberculosis Treatment under Programmatic Conditions in Urban Tanzania. PLoS One. 2016;11(8):e0161171. doi: 10.1371/journal.pone.0161171 27513331

20. Mlotshwa M, Abraham N, Beery M, Williams S, Smit S, Uys M, et al. Risk factors for tuberculosis smear non-conversion in Eden district, Western Cape, South Africa, 2007–2013: a retrospective cohort study. BMC Infect Dis [Internet]. 2016;16(1):365. Doi 10.1186/s12879-016-1712-y

21. Mugomeri E, Bekele BS, Maibvise C, Tarirai C. Trends in diagnostic techniques and factors associated with tuberculosis treatment outcomes in Lesotho, 2010–2015. South African J Infect Dis [Internet]. 2018;33(1):18–23. doi: 10.1080/23120053.2017.1376545

22. Belachew A, Kebamo S, Teklie T, Alemkere G. Poor treatment outcomes and its determinants among tuberculosis patients in selected health facilities in East Wollega, Western Ethiopia. PLoS One [Internet]. 2018;13(10). https://doi.org/10.1371/journal.pone.0206227

23. Nafae R, Elshahat H, Said A, Ibrahim M. Reviewing treatment outcomes of tuberculosis patients at Zagazig Chest Hospital (2008–2012). Egypt J Chest Dis Tuberc [Internet]. 2017;66(4):623–30. 10.1016/j.ejcdt.2017.10.006

24. Nanzaluka FH, Chibuye S, Kasapo CC, Langa N, Nyimbili S, Moonga G, et al. Factors associated with unfavourable tuberculosis treatment outcomes in Lusaka, Zambia, 2015: a secondary analysis of routine surveillance data. Pan Afr Med J. 2019 Apr 8;32:159. doi: 10.11604/pamj.2019.32.159.18472 31308862

25. Djouma FN, Noubom M, Ngomba AV, Donfack H, Kouomboua PSM, Saah MAF. Determinants of death among tuberculosis patients in a semi urban diagnostic and treatment centre of Bafoussam, West Cameroon: a retrospective case-control study. Pan Afr Med J [Internet]. 2015;22:253.

26. Oshi SN, Alobu I, Ukwaja KN, Oshi DC. Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria. Epidemiol. Infect. (2015), 143, 932–942. doi: 10.1017/S095026881400291X 25355040

27. Peltzer K, Louw JS. Prevalence and associated factors of tuberculosis treatment outcome among hazardous or harmful alcohol users in public primary health care in South Africa. Afr Health Sci [Internet]. 2014 Mar;14(1):157–66.

28. Ali Saleh AA, Hayat A, Azhar Syed SA. Evaluating treatment outcomes and durations among cases of smear-positive pulmonary tuberculosis in Yemen: A prospective follow-up study. J Pharm Policy Pract. 2017;10(1):1–10. doi: 10.1186/s40545-017-0124-8 29214026

29. Ukwaja KN, Oshib DC, Oshib SN, Alobuc I. Profile and treatment outcome of smear-positive TB patients who failed to smear convert after 2 months of treatment in Nigeria. Trans R Soc Trop Med Hyg [Internet]. 2014;108(7):431–8. doi: 10.1093/trstmh/tru070 24846911

30. Wondale B, Medihn G, Teklu T, Mersha W, Tamirat M, Ameni G. A retrospective study on tuberculosis treatment outcomes at Jinka General Hospital, southern Ethiopia. BMC Res Notes [Internet]. 2017;10(1):680. https://doi.org/10.1371/journal.pone.0206227

31. Worku S, Derbie A, Mekonnen D, Biadglegne F. Treatment outcomes of tuberculosis patients under directly observed treatment short-course at Debre Tabor General Hospital, northwest Ethiopia: Nine-years retrospective study. Infect Dis Poverty [Internet]. 2018;7(1). https://doi.org/10.1186/s40249-018-0395-6

32. Yoko JL, Tumbo JM, Mills AB, Kabongo CD. Characteristics of pulmonary tuberculosis patients in Moses Kotane region North West Province, South Africa. South African Fam Pract [Internet]. 2017;59(2):78–81. doi: 10.1080/20786190.2016.1272249

33. Zenebea T, Teferab E. Tuberculosis treatment outcome and associated factors among smear-positive pulmonary tuberculosis patients in Afar, Eastern Ethiopia: a retrospective study. Brazilian J Infect Dis [Internet]. 2016;20(6):635–6. https://doi.org/10.1016/j.bjid.2016.07.012

34. Zenebe Y, Adem Y, Mekonnen D, Derbie A, Bereded F, Bantie M, et al. Profile of tuberculosis and its response to anti-TB drugs among tuberculosis patients treated under the TB control programme at Felege-Hiwot Referral Hospital, Ethiopia. BMC Public Health. 2016 Aug;16:688. doi: 10.1186/s12889-016-3362-9 27485507

35. Cailleaux-Cezar M, Loredo C, Silva JRL, Conde MB. Impact of smoking on sputum culture conversion and pulmonary tuberculosis treatment outcomes in Brazil: a retrospective cohort study TT—Impacto do tabagismo na conversão de cultura e no desfecho do tratamento da tuberculose pulmonar no Brasil: estudo d. J Bras Pneumol [Internet]. 2018;44(2):99–105. https://doi.org/10.1590/S1806-37562017000000161

36. Calle AM, Cuartas JM, Álvarez T. Factors associated with successful treatment of tuberculosis patients in Medellin, 2014. CES salud pública. 2017; 8 (7): 34–47.

37. Djibuti M, Mirvelashvili E, Makharashvili N, Magee MJ. Household income and poor treatment outcome among patients with tuberculosis in Georgia: a cohort study. BMC Public Health. 2014 Jan;14:88. doi: 10.1186/1471-2458-14-88 24476154

38. Lackey B, Seas C, Van der Stuyft P, Otero L. Patient Characteristics Associated with Tuberculosis Treatment Default: A Cohort Study in a High-Incidence Area of Lima, Peru. PLoS One. 2015;10(6):e0128541. doi: 10.1371/journal.pone.0128541 26046766

39. Maciel EL, Reis-Santos B. Determinants of tuberculosis in Brazil: from conceptual framework to practical application. Rev Panam Salud Publica [Internet]. 2015;38(1):28–34.

40. Magee MJ, Kempker RR, Kipiani M, Gandhi NR, Darchia L, Tukvadze N, et al. Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia. Int J Tuberc Lung Dis [Internet]. 2015 Jun;19(6):685–92. https://doi.org/10.5588/ijtld.14.0811

41. Pereira JC, Silva MR, Costa RR, Guimarães MD, Leite IC. Profile and follow-up of patients with tuberculosis in a priority city in Brazil TT—Perfil e seguimento dos pacientes com tuberculose em município prioritário no Brasil. Rev Saude Publica [Internet]. 2015;49. doi: 10.1590/S0034-8910.2015049005304 25741659

42. Reis-Santos B, Pellacani-Posses I, Macedo LR, Golub JE, Riley LW, Maciel EL, et al. Directly observed therapy of tuberculosis in Brazil: Associated determinants and impact on treatment outcome. Int J Tuberc Lung Dis [Internet]. 2015 Oct;19(10):1188–93. https://doi.org/10.5588/ijtld.14.0776

43. Romanowski K, Chiang L, Roth D, Krajden M, Tang P, Cook V, et al. Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada. BMC Infect Dis [Internet]. 2017 Sep;17(1):604. doi: 10.1186/s12879-017-2706-0 28870175

44. Silva MR, Pereira JC, Costa RR, Dias JA, Guimarães MD, Leite IC. Drug addiction and alcoholism as predictors for tuberculosis treatment default in Brazil: A prospective cohort study. Epidemiol Infect [Internet]. 2017;145(16):3516–24. doi: 10.1017/S0950268817002631 29173226

45. Snyder RE, Marlow MA, Phuphanich ME, Riley LW, Maciel EL. Risk factors for differential outcome following directly observed treatment (DOT) of slum and non-slum tuberculosis patients: A retrospective cohort study. BMC Infect Dis [Internet]. 2016;16(1). doi: 10.1186/s12879-016-1835-1 27647383

46. Viana PV, Goncalves MJ, Basta PC. Ethnic and Racial Inequalities in Notified Cases of Tuberculosis in Brazil. PLoS One. 2016;11(5):e0154658. doi: 10.1371/journal.pone.0154658 27176911

47. Viegas AM, Miranda SS, Haddad JP, Ceccato MG, Carvalho WS. Association of outcomes with comprehension, adherence and behavioral characteristics of tuberculosis patients using fixed-dose combination therapy in contagem, Minas Gerais, Brazil. Rev Inst Med Trop Sao Paulo [Internet]. 2017;59. https://doi.org/10.1590/S1678-9946201759028

48. Ahmad T, Khan MM, Khan MM, Ejeta E, Karami M, Ohia C, et al. Treatment outcome of tuberculosis patients under directly observed treatment short course and its determinants in Shangla, Khyber-Pakhtunkhwa, Pakistan: A retrospective study. Int J Mycobacteriology [Internet]. 2017;6(4):360–4. doi: 10.4103/ijmy.ijmy_69_17 29171450

49. Mohammadzadeh KA, Ghayoomi A, Maghsoudloo D. Evaluation of factors associated with failure of tuberculosis treatment under DOTS in northern Islamic Republic of Iran. East Mediterr Health J. 2016 Apr;22(2):87–94. doi: 10.26719/2016.22.2.87 27180736

50. Alqahtani S, Kashkary A, Asiri A, Kamal H, Binongo J, Castro K, et al. Impact of mobile teams on tuberculosis treatment outcomes, Riyadh Region, Kingdom of Saudi Arabia, 2013–2015. J Epidemiol Glob Health [Internet]. 2018;7:S29–33. https://doi.org/10.1016/j.jegh.2017.09.005

51. Atif M, Sulaiman SA, Shafie AA, Ali I, Asif M, Babar ZU. Treatment outcome of new smear positive pulmonary tuberculosis patients in Penang, Malaysia. BMC Infect Dis. 2014 Jul;14:399. doi: 10.1186/1471-2334-14-399 25037452

52. Babalik A, Kiziltas S, Gencer S, Kilicaslan Z. An investigation into the relationship between region specific quality of life and adverse tuberculosis treatment outcomes in Istanbul, Turkey. Rev Port Pneumol [Internet]. 2014;20(5):248–53. https://doi.org/10.1016/j.rppneu.2014.01.003

53. Leung CC, Yew WW, Chan CK, Chang KC, Law WS, Lee SN, et al. Smoking adversely affects treatment response, outcome and relapse in tuberculosis. Eur Respir J [Internet]. 2015;45(3):738–45. https://doi.org/10.1183/09031936.00114214

54. Choi H, Lee M, Chen R, Kim Y, Yoon S, Joh J, et al. Predictors of pulmonary tuberculosis treatment outcomes in South Korea: A prospective cohort study, 2005–2012. BMC Infect Dis [Internet]. 2014;14(1).

55. Gadoev J, Asadov D, Tillashaykhov M, Tayler-Smith K, Isaakidis P, et al. Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study. PLoS ONE. 2015;10(6): e0128907. doi: 10.1371/journal.pone.0128907 26075615

56. Hongguang C, Min L, Shiwen J, Fanghui G, Shaoping H, Tiejie G, et al. Impact of diabetes on clinical presentation and treatment outcome of pulmonary tuberculosis in Beijing. Epidemiol Infect [Internet]. 2015;143(1):150–6. doi: 10.1017/S095026881400079X 24717600

57. Jackson C, Stagg HR, Doshi A, Pan D, Sinha A, Batra R, et al. Tuberculosis treatment outcomes among disadvantaged patients in India. Public Heal Action [Internet]. 2017;7(2):134–40. https://doi.org/10.5588/pha.16.0107

58. Khaing PS, Kyaw NT, Satyanarayana S, Oo NL, Aung TH, Oo HM, et al. Treatment outcome of tuberculosis patients detected using accelerated vs. passive case finding in Myanmar. Int J Tuberc Lung Dis [Internet]. 2018;22(10):1145–51. https://doi.org/10.5588/ijtld.18.0038

59. Khazaei S, Hassanzadeh J, Rezaeian S, Ghaderi E, Khazaei S, Hafshejani A, et al. Treatment outcome of new smear positive pulmonary tuberculosis patients in Hamadan, Iran: A registry-based cross-sectional study. Egypt J Chest Dis Tuberc [Internet]. 2016;65(4):825–30. https://doi.org/10.1016/j.ejcdt.2016.05.007

60. Kwon YS, Kim YH, Song JU, Jeon K, Song J, Ryu YJ, et al. Risk factors for death during pulmonary tuberculosis treatment in Korea: a multicenter retrospective cohort study. J Korean Med Sci [Internet]. 2014 Sep;29(9):1226–31. https://doi.org/10.3346/jkms.2014.29.9.1226

61. Liew SM, Khoo EM, Ho BK, Lee YK, Mimi O, Fazlina MY, et al. Tuberculosis in malaysia: Predictors of treatment outcomes in a national registry. Int J Tuberc Lung Dis [Internet]. 2015;19(7):764–71. https://doi.org/10.5588/ijtld.14.0767A

62. Lin Y, Enarson DA, Du J, Dlodlo RA, Chiang CY, Rusen ID. Risk factors for unfavourable treatment outcome among new smear-positive pulmonary tuberculosis cases in China. Public Heal Action [Internet]. 2017;7(4):299–303. https://doi.org/10.5588/pha.17.0056

63. Lo H-Y, Yang S-L, Lin H-H, Bai K-J, Lee J-J, Lee T-I, et al. Does enhanced diabetes management reduce the risk and improve the outcome of tuberculosis? Int J Tuberc Lung Dis [Internet]. 2016;20(3):376–82. https://doi.org/10.5588/ijtld.15.0654

64. Lwin ZM, Sahu SK, Owiti P, Chinnakali P, Majumdar SS. Public-private mix for tuberculosis care and control in Myanmar: A strategy to scale up? Public Heal Action [Internet]. 2017;7(1):15–20. https://doi.org/10.5588/pha.16.0103

65. Morishita F, Gonzales AM, Lew W, Hyun K, Yadav RP, Reston JC, et al. Bringing state-of-The-Art diagnostics to vulnerable populations: The use of a mobile screening unit in active case finding for tuberculosis in Palawan, the Philippines. PLoS One [Internet]. 2017;12(2). doi: 10.1371/journal.pone.0171310 28152082

66. Mukhtar F, Butt ZA. Cohort profile: the diabetes-tuberculosis treatment outcome (DITTO) study in Pakistan. BMJ Open. 2016 Dec;6(12):e012970. doi: 10.1136/bmjopen-2016-012970 27913560

67. Mundra A, Deshmukh P, Dawale A. Magnitude and determinants of adverse treatment outcomes among tuberculosis patients registered under Revised National Tuberculosis Control Program in a Tuberculosis Unit, Wardha, Central India: A record-based cohort study. J Epidemiol Glob Health [Internet]. 2017;7(2):111–8. https://doi.org/10.1016/j.jegh.2017.02.002

68. Mundra A, Deshmukh P, Dawale A. Determinants of adverse treatment outcomes among patients treated under Revised National Tuberculosis Control Program in Wardha, India: Case–control study. Med J Armed Forces India [Internet]. 2018;74(3):241–9. https://doi.org/10.1016/j.mjafi.2017.07.008

69. Ni W, Yan M, Hong L, Jian D, Hui Z, Heng X, et al. Risk of Treatment Failure in Patients with Drug-susceptible Pulmonary Tuberculosis in China. Biomed Environ Sci [Internet]. 2016;29(8):612–7.

70. Piparva K.G. Treatment outcome of tuberculosis patients on dots therapy for category 1 and 2 at district tuberculosis centre. Int J Pharm Sci Res [Internet]. 2017;8(1):207–12. doi: 10.13040/IJPSR.0975-8232.8(1).207-12

71. Rahimy N, Luvira V, Charunwatthana P, Iamsirithaworn S, Sutherat M, Phumratanaprapin W, et al. Predicting factors of treatment failure in smear positive pulmonary tuberculosis: A retrospective cohort study in Bangkok using a combination of symptoms and sputum smear/chest radiography. J Med Assoc Thail [Internet]. 2018;101(2):181–8.

72. Rao P, Chawla K, Shenoy V, Mukhopadhyay C, Brahmavar V, Kamath A, et al. Study of drug resistance in pulmonary tuberculosis cases in south coastal Karnataka. J Epidemiol Glob Health [Internet]. 2015;5(3):275–81.

73. Sadykova L, Abramavičius S, Maimakov T, et al. A retrospective analysis of treatment outcomes of drug-susceptible TB in Kazakhstan, 2013–2016. Medicine (Baltimore). 2019;98(26):e16071. doi: 10.1097/MD.0000000000016071 31261516

74. Schwitters A, Kaggwa M, Omiel P, Nagadya G, Kisa N, Dalal S. Tuberculosis incidence and treatment completion among Ugandan prison inmates. Int J Tuberc Lung Dis [Internet]. 2014;18(7):781–786+i. https://doi.org/10.5588/ijtld.13.0934

75. Shahrezaei M, Reza Maracy MR, Farid F. Factors affecting mortality and treatment completion of tuberculosis patients in Isfahan Province from 2006 to 2011. Int J Prev Med [Internet]. 2015;2015-Septe. Doi:10.4103/2008-7802.165157A

76. Thomas BE, Thiruvengadam K, S. R, Kadam D, Ovung S, Sivakumar S, et al. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burden that cannot be ignored. PLoS ONE. 2019. 14(7): e0220507. 10.1371/journal.pone.0220507 31365583

77. Wang X, Cai J, Wang D, Wang Q, Liang H, Ma A, et al. Registration and management of community patients with tuberculosis in north-west China. Public Health [Internet]. 2015;129(12):1585–90. https://doi.org/10.1016/j.puhe.2015.09.005

78. Wang X-M, Yin S-H, Du J, Du M-L, Wang P-Y, Wu J, et al. Risk factors for the treatment outcome of retreated pulmonary tuberculosis patients in China: an optimized prediction model. Epidemiol Infect. 2017 Jul;145(9):1805–14. Doi:10.1017/S0950268817000656 28397611

79. Wen Y, Zhang Z, Li X, Xia D, Ma J, Dong Y, et al. Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: A retrospective study. BMC Infect Dis [Internet]. 2018;18(1). https://doi.org/10.1186/s12879-018-3019-7

80. He X-C, Tao N-N, Liu Y, Zhang X-X, Li H-C. Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China. BMC Infect Dis. 2017 Aug;17(1):555. doi: 10.1186/s12879-017-2652-x 28793873

81. Yoon Y, Jung J, Jeon E, Seo H, Ryu Y, Yim J, et al. The effect of diabetes control status on treatment response in pulmonary tuberculosis: A prospective study. Thorax [Internet]. 2017;72(3):263–70. doi: 10.1136/thoraxjnl-2015-207686 27553224

82. Zhang Q, Gaafer M, El-Bayoumy I. Determinants of default from pulmonary tuberculosis treatment in Kuwait. Sci World J [Internet]. 2014;2014. https://doi.org/10.1155/2014/672825

83. Aibana O, Slavuckij A, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, et al. Patient predictors of poor drug sensitive tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. F1000Research [Internet]. 2018;6. https://doi.org/10.12688/f1000research.12687.1

84. Cruz-Ferro E, Ursúa-Díaz MI, Taboada-Rodríguez JA, Hervada-Vidal X, Anibarro L, Túñez V. Epidemiology of tuberculosis in galicia, spain, 16 years after the launch of the galician tuberculosis programme. Int J Tuberc Lung Dis [Internet]. 2014;18(2):134–40. https://doi.org/10.5588/ijtld.13.0419

85. Dias M, Gaio R, Sousa P, Abranches M, Gomes M, Oliveira O, et al. Tuberculosis among the homeless: Should we change the strategy? Int J Tuberc Lung Dis [Internet]. 2017 Mar;21(3):327–32. https://doi.org/10.5588/ijtld.16.0597

86. Gaborita BJ, Revest M, Roblotc F, Maakaroun-Vermessed Z, Bemere P, Guimard T, et al. Characteristics and outcome of multidrug-resistant tuberculosis in a low-incidence area. Med Mal Infect [Internet]. 2018;48(7):457–64. https://doi.org/10.1016/j.medmal.2018.04.400

87. Holden IK, Lillebaek T, Seersholm N, Andersen PH, Wejse C, Johansen IS. Predictors for Pulmonary Tuberculosis Treatment Outcome in Denmark 2009–2014. Sci Rep 9, 12995 (2019) doi: 10.1038/s41598-019-49439-9 31506499

88. Karo B, Hauer B, Hollo V, Van-Der-Werf MJ, Fiebig L, Haas W. Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002‒2011. Eurosurveillance [Internet]. 2016;20(48):30087. 10.2807/1560-7917

89. Lucenko I, Riekstina V, Perevoscikovs J, Mozgis D, Khogali M, Gadoev J, et al. Treatment outcomes among drug-susceptible tuberculosis patients in Latvia, 2006–2010. Public Heal Action [Internet]. 2014;4:S54–8. https://doi.org/10.5588/pha.14.0040

90. Moreno-Gómez M, Alonso-Sardón M, Iglesias-de-Sena H, Aranha de Macèdo L, Mirón-Canelo J. Prospective follow-up of results of tuberculosis treatment. Rev Esp Quimioter [Internet]. 2014;27(4):244–51.

91. Priedeman M, Curtis S, Angeles G, Mullen S, Senik T. Evaluating the impact of social support services on tuberculosis treatment default in Ukraine. PLoS One [Internet]. 2018;13(8). https://doi.org/10.1371/journal.pone.0199513

92. Przybylski G, Dąbrowska A, Trzcińska H. Alcoholism and other socio-demographic risk factors for adverse TB-drug reactions and unsuccessful tuberculosis treatment–data from ten years’ observation at the Regional Centre of Pulmonology, Bydgoszcz, Poland. Med Sci Monit, 2014; 20: 444–453. doi: 10.12659/MSM.890012 24643127

93. Rodríguez-Valín E, Villarrubia Enseñat S, Díaz García O, Martínez Sánchez EV. Risk Factors for Potentially Unsuccessful Results and Mortality during Tuberculosis Treatment in Spain. Rev Esp Salud Publica [Internet]. 2015;89(5):459–70.

94. Alo A, Gounder S, Graham S. Clinical characteristics and treatment outcomes of tuberculosis cases hospitalised in the intensive phase in Fiji. Public Heal Action [Internet]. 2014;4(3):164–8. https://doi.org/10.5588/pha.14.0022

95. Itogo N, Hill C, Bissell K, Harries A, Viney K, Gounder S. Tuberculosis notifications, characteristics and treatment outcomes: Urban vs. rural Solomon Islands, 2000–2011. Public Heal Action [Internet]. 2014;4(SUPPL. 1):S25–8. https://doi.org/10.5588/pha.13.0078

96. Scheelbeek P, Wirix A, Hatta M, Usman R, Bakker M, et al. Risk factors for poor tuberculosis treatment outcomes in Makassar, Indonesia. Southeast Asian J Trop Med Public Health [Internet]. 2014 Jul;45(4):853–8.

97. Tagaro M, Harries A, Kool B, Ram S, Viney K, Marais B, et al. Tuberculosis case burden and treatment outcomes in children, adults and older adults, Vanuatu, 2007–2011. Public Heal Action [Internet]. 2014;4(SUPPL. 1):S14–8. https://doi.org/10.5588/pha.13.0074

98. Agbor A, Bigna J, Billong S, Tejiokem M, Ekali G, Plottel C, et al. Factors associated with death during tuberculosis treatment of patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-year hospital-based retrospective cohort study (2006–2013). PLoS One [Internet]. 2014;9(12). doi: 10.1371/journal.pone.0115211 25506830

99. Ambadekar NN, Zodpey SP, Soni RN, Lanjewar SP. Treatment outcome and its attributes in TB-HIV co-infected patients registered under Revised National TB Control Program: A retrospective cohort analysis. Public Health [Internet]. 2015;129(6):783–9. https://doi.org/10.1016/j.puhe.2015.03.006

100. Belayneha M, Giday K, Lemma H. Treatment outcome of human immunodeficiency virus and tuberculosis co-infected patients in public hospitals of eastern and southern zone of Tigray region, Ethiopia. Brazilian J Infect Dis [Internet]. 2015;19(1):47–51. https://doi.org/10.1016/j.bjid.2014.09.002

101. Do-Prado TN, Rajan J V, Miranda AE, Dias EDS, Cosme LB, Possuelo LG, et al. Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment outcomes in TB-HIV co-infected patients in Brazil: a hierarchical polytomous analysis. Braz J Infect Dis. 2017 Mar;21(2):162–70. https://doi.org/10.1016/j.bjid.2016.11.006 27936379

102. Engelbrecht M, Kigozi N, Chikobvu P, Botha S, Rensburg H. Unsuccessful TB treatment outcomes with a focus on HIV co-infected cases: a cross-sectional retrospective record review in a high-burdened province of South Africa. BMC Health Serv Res [Internet]. 2017;17(1):470. doi: 10.1186/s12913-017-2406-x 28693508

103. Jacobson K, Moll A, Friedland G, Shenoi S. Successful tuberculosis treatment outcomes among HIV/TB coinfected patients down-referred from a district hospital to primary health clinics in rural South Africa. PLoS One [Internet]. 2015;10(5). doi: 10.1371/journal.pone.0125588

104. Lawal A, Aliyu M, Galadanci N, Musa B, Lawan U, Bashir U, et al. The impact of rural residence and HIV infection on poor tuberculosis treatment outcomes in a large urban hospital: A retrospective cohort analysis. Int J Equity Health [Internet]. 2018;17(1). doi: 10.1186/s12939-017-0714-8 29310659

105. Mahtab S, Coetzee D. Influence of HIV and other risk factors on tuberculosis. SAMJ South African Med J [Internet]. 2017;107(5):428–34.

106. Monge S, Diez M, Pulido F, Iribarren J, Campins A, Arazo P, et al. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes. Int J Tuberc Lung Dis [Internet]. 2014;18(6):700–708+i. https://doi.org/10.5588/ijtld.13.0778

107. Parchure R, Kulkarni V, Gangakhedkar G, Swaminathan S. Treatment outcomes of daily anti-tuberculosis treatment in HIV-infected patients seeking care at a private clinic in India. Int J Tuberc Lung Dis [Internet]. 2016;20(10):1348–53. https://doi.org/10.5588/ijtld.16.0098

108. Sinshaw Y, Alemu S, Fekadu A, Gizachew M. Successful TB treatment outcome and its associated factors among TB/HIV co-infected patients attending Gondar University Referral Hospital, Northwest Ethiopia: An institution based cross-sectional study. BMC Infect Dis [Internet]. 2017 Feb;17(1):132. doi: 10.1186/s12879-017-2238-7 28178936

109. Tanue EA, Nsagha DS, Njamen TN, Assob NJC. Tuberculosis treatment outcome and its associated factors among people living with HIV and AIDS in Fako Division of Cameroon. PLoS ONE. 2019 14(7): e0218800. 10.1371/journal.pone.0218800 31361755

110. Theingia P, Harries AD, Thet-Waid K, Shewade HD, Sawd S, Winf T, et al. National scale-up of tuberculosis-human immunodeficiency virus collaborative activities in Myanmar from 2005 to 2016 and tuberculosis treatment outcomes for patients with human immunodeficiency virus-positive tuberculosis in the Mandalay Region in 2015. Trans R Soc Trop Med Hyg [Internet]. 2017;111(9):402–9. doi: 10.1093/trstmh/trx073 29361150

111. Torrens A, Bartholomay P, Silva S, Khogali M, Verdonck K, Bissell K. HIV testing, antiretroviral therapy, and treatment outcomes in new cases of tuberculosis in Brazil, 2011. Rev Panam Salud Publica [Internet]. 2016;39(1):26–31.

112. Wannheden C, Norrby M, Berggren I, Westling K. Tuberculosis among HIV-infected patients in Stockholm, Sweden, 1987–2010: Treatment outcomes and adverse reactions. Scand J Infect Dis [Internet]. 2014 May;46(5):331–9. doi: 10.3109/00365548.2013.878033 24512373

113. Alavi SM, Salmanzadeh S, Bakhtiyariniya P, Albagi A, Hemmatnia F, Alavi L. Prevalence and treatment outcome of pulmonary and extrapulmonary pediatric tuberculosis in southwestern Iran. Casp J Intern Med [Internet]. 2015;6(4):213–9.

114. Flick RJ, Kim MH, Simon K, Munthali A, Hosseinipour M, Nora E. Rosenberg 2,5, et al. Burden of disease and risk factors for death among children treated for tuberculosis in Malawi. Int J Tuberc Lung Dis [Internet]. 2016 Aug;20(8):1046–54. doi: 10.5588/ijtld.15.0928 27393538

115. Hamid M, Brooks MB, Madhani F, Ali H, Naseer MJ, The Childhood Tuberculosis Karachi Group, et al. Risk factors for unsuccessful tuberculosis treatment outcomes in children. PLoS ONE. 2019 14(9): e0222776. 10.1371/journal.pone.0222776 31553758

116. Laghari M, Sulaiman SA, Khan AH, Memon N. Epidemiology of tuberculosis and treatment outcomes among children in Pakistan: A 5 year retrospective study. PeerJ [Internet]. 2018;2018(7). doi: 10.7717/peerj.5253 30065869

117. Ohene SA, Fordah S, Dela Boni P. Childhood tuberculosis and treatment outcomes in Accra: a retrospective analysis. BMC Infect Dis. 2019;19(1):749. Published 2019 Aug 28. doi: 10.1186/s12879-019-4392-6 31455234

118. Tilahun G, Gebre-Selassie S. Treatment outcomes of childhood tuberculosis in Addis Ababa: a five-year retrospective analysis. BMC Public Health [Internet]. 2016;16:612. doi: 10.1186/s12889-016-3193-8 27443308

119. Turkova A, Chappell E, Chalermpantmetagul S, Negra MD, Volokha A, Primak N, et al. Tuberculosis in HIV-infected children in Europe, Thailand and Brazil: paediatric TB-HIV EuroCoord study. Int J Tuberc Lung Dis [Internet]. 2016;20(11):1448–56. https://doi.org/10.5588/ijtld.16.0067

120. Addis-Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health. 2017 Mar;22(3):351–62. Doi:10.1111/tmi.12826 27978594

121. Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, et al. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. 2017;1–7. doi: 10.1186/s12879-017-2230-2

122. Altena R, Vries G, Haar CH, Lange WC, Magis-Escurra C, Hof S, et al. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009. Int J Tuberc Lung Dis. 2015 Apr;19(4):406–12. https://doi.org/10.5588/ijtld.14.0838 25859995

123. Atif M, Bashir A, Ahmad N, Fatima RK, Saba S, Scahill S. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients. BMC Infect Dis [Internet]. 2017 Sep;17(1):655. doi: 10.1186/s12879-017-2746-5 28962599

124. Bastard M, Sanchez-Padilla E, Cros P, Khamraev AK, Parpieva N, Tillyashaykov M, et al. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study. PLoS One [Internet]. 2018;13(3). https://doi.org/10.1371/journal.pone.0193491

125. Brust J, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, et al. Improved Survival and Cure Rates with Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa. Clin Infect Dis [Internet]. 2018;66(8):1246–53. 10.1093/cid/cix1125/4774985

126. Cegielski JP, Kurbatova E, Van der Walt M, Brand J, Ershova J, Tupasi T, et al. Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance. Clin Infect Dis [Internet]. 2015 Feb;62(4):418–30.

127. Chen Y, Yuan Z, Shen X, Wu J, Wu Z, Xu B. Time to multidrug-resistant tuberculosis treatment initiation in association with treatment outcomes in Shanghai, China. Antimicrob Agents Chemother [Internet]. 2018;62(4). https://doi.org/10.1128/AAC.02259-17

128. Chiang S, Starke J, Miller AC, Cruz A, Castillo H, Valdivia WJ, et al. Baseline Predictors of Treatment Outcomes in Children with Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis [Internet]. 2016;63(8):1063–71. doi: 10.1093/cid/ciw489 27458026

129. Demile B, Amare Zenebu A, Shewaye H, Xia S, Guadie A. Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. BMC Infect Dis [Internet]. 2018;18(1). https://doi.org/10.1186/s12879-018-3167-9

130. Duraisamy K, Mrithyunjayan S, Ghosh S, Nair SA, Balakrishnan S, Subramoniapillai J, et al. Does alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India. Ann Am Thorac Soc [Internet]. 2014 Jun;11(5):712–5. doi: 10.1513/AnnalsATS.201312-447OC 24735096

131. Francis JR, Manchikanti P, Blyth CC, Denholm J, Lowbridge C, Coulter C. Multidrug-resistant tuberculosis in Western Australia, 1998–2012. Med J Aust [Internet]. 2014;200(6):328–32. https://doi.org/10.5588/ijtld.17.0412

132. Heysell SK, Ogarkov OB, Zhdanova S, Zorkaltseva E, Shugaeva S, Gratz J, et al. Undertreated HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia. Int J Tuberc Lung Dis [Internet]. 2016 Feb;20(2):187–92. doi: 10.5588/ijtld.14.0961 26792470

133. Ibrahim E, Baess AI, Al-Messery MA. Pattern of prevalence, risk factors and treatment outcomes among Egyptian patients with multidrug resistant tuberculosis. Egypt J Chest Dis Tuberc [Internet]. 2017;66(3):405–11. https://doi.org/10.1016/j.ejcdt.2016.11.002

134. Jagielski T, Brzostek A, van Belkum A, Dziadek J, Augustynowicz-Kopec E, Zwolska Z. A close-up on the epidemiology and transmission of multidrug-resistant tuberculosis in Poland. Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):41–53. doi: 10.1007/s10096-014-2202-z 25037868

135. Janmeja AK, Aggarwal D, Dhillon R. Factors predicting treatment success in multi-drug resistant tuberculosis patients treated under programmatic conditions. Indian J Tuberc [Internet]. 2018;65(2):135–9. https://doi.org/doi:10.1016/j.ijtb.2017.12.015

136. Javaid A, Shaheen Z, Shafqat M, Khan AH, Ahma N. Risk factors for high death and loss-to-follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic management unit. Am J Infect Control [Internet]. 2017;45(2):190–3. https://doi.org/10.1016/j.ajic.2016.07.026

137. Javaid A, Ullah I, Masud H, Basit A, Ahmad W, Butt ZA, et al. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study. Clin Microbiol Infect [Internet]. 2018 Jun;24(6):612–7. https://doi.org/10.1016/j.cmi.2017.09.012

138. Jensenius M, Winje BA, Blomberg B, Mengshoel AT, Von der Lippe B, Hannula R, et al. Multidrug-resistant tuberculosis in Norway: A nationwide study, 1995–2014. Int J Tuberc Lung Dis [Internet]. 2016;20(6):786–92. https://doi.org/10.5588/ijtld.15.0895

139. Kawatsu L, Uchimura K, Izumi K, Ohkado A, Yoshiyama T. Treatment outcome of multidrug-resistant tuberculosis in Japan—the first cross-sectional study of Japan tuberculosis surveillance data. BMC Infect Dis. 2018 Aug;18(1):445. https://doi.org/10.1186/s12879-018-3353-9 30170549

140. Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I, et al. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan. Saudi Med J [Internet]. 2015 Dec;36(12):1463–71. doi: 10.15537/smj.2015.12.12155 26620989

141. Liu Q, Lu P, Martinez L, Yang H, Lu W, Ding X, et al. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. BMC Infect Dis. 2018 Mar;18(1):114. https://doi.org/10.1186/s12879-018-3021-0 29510666

142. Marais E, Mlambo CK, Lewis JJ, Rastogi N, Zozio T, Grobusch MP, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa. Infection. 2014 Apr;42(2):405–13. doi: 10.1007/s15010-013-0572-2 24363208

143. Perez-Navarro LM, Restrepo BI, Fuentes-Dominguez FJ, Duggirala R, Morales-Romero J, Lopez-Alvarenga JC, et al. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes. Tuberculosis [Internet]. 2017;103:83–91. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L614301639 https://doi.org/10.1016/j.tube.2017.01.006

144. Muñoz-Torrico M, Caminero-Lunab J, Battista-Migliori G, D’Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, et al. Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis. Arch Bronconeumol [Internet]. 2017;53(5):245–50. https://doi.org/10.1016/j.arbres.2016.10.021

145. Nair D, Velayutham B, Kannan T, Tripathy JP, Harries AD, Natrajan M, et al. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. Public Heal Action [Internet]. 2017;7(1):32–8. https://doi.org/10.5588/pha.16.0055

146. Pang Y, Lu J, Huo F, Ma Y, Zhao L, Li Y, et al. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review. J Infect [Internet]. 2017 Nov;75(5):433–40. doi: 10.1016/j.jinf.2017.08.005 28804028

147. Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, et al. Unacceptable treatment outcomes and associated factors among India’s initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): Evidence leading to policy enhancement. PLoS One. 2018;13(4):e0193903. https://doi.org/10.1371/journal.pone.0193903 29641576

148. Phuong N, Nhung N, Hoa N, Thuy T, Takarinda K, Tayler-Smith K, et al. Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam. Public Heal Action [Internet]. 2016;6(1):25–31. https://doi.org/10.5588/pha.15.0068

149. Schnippel K, Shearer K, Evans D, Berhanu R, Dlamini S, Ndjeka N. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. Int J Infect Dis [Internet]. 2015;39:89–94. https://doi.org/10.1016/j.ijid.2015.09.002

150. Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis. 2017;22(1):17–25. https://doi.org/10.5588/ijtld.17.0498 29149917

151. Udwadia ZF, Moharil G. Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai. Lung India [Internet]. 2014;31(4):336–41. doi: 10.4103/0970-2113.142101 25378840

152. Verdecchia M, Keus K, Blankley S, Vambe D, Ssonko C, Piening T, et al. Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011–2013. PLoS One [Internet]. 2018;13(10). 10.1371/journal.pone.0205601

153. Viana PV de S, Redner P, Ramos JP. Factors associated with loss to follow-up and death in cases of drug-resistant tuberculosis (DR-TB) treated at a reference center in Rio de Janeiro, Brazil. Cad Saúde Pública [Internet]. 2018;34(5):e00048217—e00048217. doi: 10.1590/0102-311X00048217 29768580

154. Villegas L, Otero L, Sterling T, Huaman M, Van der Stuyft P, Gotuzzo E, et al. Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru. PLoS One [Internet]. 2016;11(4):e0152933. doi: 10.1371/journal.pone.0152933 27045684

155. Xu C, Pang Y, Li R, Ruan Y, Wang L, Chen M, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect [Internet]. 2018;76(4):348–53. https://doi.org/10.1016/j.jinf.2017.12.017

156. Zhang L, Meng Q, Chen S, Zhang M, Chen B, Wu B, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009–2013, Clinical Microbiology and Infection (2017), doi: 10.1016/j.cmi.2017.07.008

157. Zhang Q, Wu Z, Zhang Z, Sha W, Shen X, Xiao H. Efficacy and effect of free treatment on multidrug-resistant tuberculosis. Exp Ther Med [Internet]. 2016;11(3):777–82. doi: 10.3892/etm.2015.2966 26997992

158. Faustini A, Hall AJ, Perucci CA. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J 2005; 26: 503–510 doi: 10.1183/09031936.05.00103504 16135735

159. Seid MA, Ayalew MB, Muche EA, Gebreyohannes EA, Abegaz TM. Drugsusceptible tuberculosis treatment success and associated factors in Ethiopia from 2005 to 2017: a systematic review and meta-analysis. BMJ Open 2018;8:e022111 doi: 10.1136/bmjopen-2018-022111 30257846

160. Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1600803 [https://doi.org/10.1183/13993003.00803-2016]. 28331031

161. Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018 15(7): e1002595. https://doi.org/10.1371/journal.pmed.1002595 29969463

162. Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018 15(7): e1002591. 10.1371/journal.pmed.1002591 29995958

163. Do Socorro Nantua Evangelista M, Maia R, Toledo JP, De Abreu RG, Braga JU, Barreira D, et al. Second month sputum smear as a predictor of tuberculosis treatment outcomes in Brazil. BMC Res Notes [Internet]. 2018;11(1):4–9. https://doi.org/10.1186/s13104-018-3522-3

164. Ramarokoto H, Randriamiharisoa H, Rakotoarisaonina A, Rasolovavalona T, Rasolofo V, Chanteau S, et al. Bacteriological follow-up of tuberculosis treatment: A comparative study of smear microscopy and culture results at the second month of treatment. Int J Tuberc Lung Dis. 2002;6(10):909–12. 12365578

165. Juan Pablo Aguilar JP, Arriaga MB, Rodas MN, Netto E. Tabaquismo y fracaso del tratamiento de la tuberculosis pulmonar. Un estudio de casos y controles. J Bras Pneumol. 2019;45(2):e20180359. doi: 10.1590/1806-3713/e20180359

166. Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol. 1997;50(3):223–9. doi: 10.1016/s0895-4356(96)00360-5 9120519


Článek vyšel v časopise

PLOS One


2019 Číslo 12
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

KOST
Koncepce osteologické péče pro gynekology a praktické lékaře
nový kurz
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Svět praktické medicíny 5/2023 (znalostní test z časopisu)

Imunopatologie? … a co my s tím???
Autoři: doc. MUDr. Helena Lahoda Brodská, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#